Results 181 to 190 of about 33,623 (258)

Author Correction: Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. [PDF]

Nat Aging
Denk D, Singh A, Kasler HG, D'Amico D, Rey J, Alcober-Boquet L, Gorol JM, Steup C, Tiwari R, Kwok R, Argüello RJ, Faitg J, Sprinzl K, Zeuzem S, Nekljudova V, Loibl S, Verdin E, Rinsch C, Greten FR.   +18 more
europepmc   +1 more source

Repeatability of keratometry depending on tear film osmolarity

Acta Ophthalmologica, Volume 104, Issue 5, Page e530-e537, August 2026.
Abstract Purpose To determine the repeatability of keratometry and astigmatism measurements of patients depending on the tear film osmolarity using three different devices. Methods In this study, 97 eyes of 97 patients with a mean age of 64.92 ± 12.07 years received three repeated measurements with the IOLMaster 700 (Carl Zeiss Meditec, Jena, Germany),
David Schneider, Klemens Paul Kaiser, Petra Davidova, Thomas Kohnen, Tyll Jandewerth   +4 more
wiley   +1 more source

Reactive agility-evidence based suggestions for improvement. [PDF]

Front Sports Act Living
Vogt L, Laukhardt F, Haser C, Banzer W, Engeroff T.   +4 more
europepmc   +1 more source

Ray‐Tracing‐Based Intraocular Lens Power Calculation in Combined Cataract Surgery and Descemet Membrane Endothelial Keratoplasty

Clinical &Experimental Ophthalmology, Volume 54, Issue 6, Page 769-778, August 2026.
ABSTRACT Background To compare the predictive accuracy of ray tracing‐based intraocular lens (IOL) power calculation formulas with the Barrett Universal II (BUII) formula in eyes with Fuchs endothelial corneal dystrophy (FECD) undergoing combined cataract surgery and Descemet membrane endothelial keratoplasty (triple DMEK).
Jan O. Weber, Klemens P. Kaiser, Jascha A. Wendelstein, H. Burkhard Dick, Thomas Kohnen, Ingo Schmack   +5 more
wiley   +1 more source

Loss of Y chromosome: proteomic signatures in human cardiovascular disease. [PDF]

Eur Heart J
Weyrich M, Windschmitt J, Abplanalp WT, Ware A, Sarakpi T, Zewinger S, Zanders L, Dimmeler S, Zeiher AM, Speer T.   +9 more
europepmc   +1 more source

Knocking Off the Street: The Subversive Writings of Hong Kong's Grassroots Kings

City &Society, Volume 38, Issue 2, August 2026.
ABSTRACT This article examines how two grassroots street artists in Hong Kong, the King of Kowloon (Tsang Tsou‐choi) and the Plumber King (Yim Chiu‐tong), intervene in the city's everyday visual order. Moving beyond celebratory collective memory narratives and easy analogies to graffiti, it frames their works as subversive urban practices that rework ...
Shizheng Liang, Zihong Zhang
wiley   +1 more source

Visual Search Performance in Children With ASD: A Combined Case-Control and Longitudinal Study. [PDF]

Autism Res
Raji N, Todorova I, Polzer L, Kleber SK, Lemler C, Schnettler L, Kitzerow-Cleven J, Kim Z, Freitag CM, Bast N.   +9 more
europepmc   +1 more source

Mandibular Overdentures on Four Immediately Loaded Mini‐Implants Versus Two‐Delayed Loaded Regular Implants: 1‐Year, Two‐Center RCT on Patient‐Reported Outcomes

Clinical Oral Implants Research, Volume 37, Issue 8, Page 983-993, August 2026.
ABSTRACT Objective This one‐year randomized clinical trial compared the effects of mandibular implant‐overdentures (IODs) on two two‐piece regular‐neck tissue‐level implants (Group A) or on four mini‐implants (Group B) with different loading protocols in edentulous patients concerning dental Patient‐Reported Outcomes (dPROs).
Martin Schimmel, Cláudio Rodrigues Leles, Nicole Schenk, Simone F. M. Janner, Beat Wallkamm, Valérie G. A. Suter, Samir Abou‐Ayash, Clemens Raabe   +7 more
wiley   +1 more source

Single-Stage Combined Embolization and Structural Allograft Reconstruction for Proximal Humerus Aneurysmal Bone Cysts in Children. [PDF]

Children (Basel)
Leiblein M, Frank J, Marzi I, Sommer K, Eichler K, Vogl T, Wagner N.   +6 more
europepmc   +1 more source

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Olamkicept up to 2400 mg in Healthy Men: Phase I, Randomized, Placebo‐Controlled, and Double‐Blind Trial

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Olamkicept is a first‐in‐class fully human fusion protein that selectively inhibits trans interleukin (IL)‐6 signaling. Previous phase I clinical trials demonstrated that single doses up to 750 mg and multiple doses up to 600 mg were safe and well tolerated in healthy men and women.
Stanislav Ignatenko, Alla Radicke, Katharina Bruzelius, Michael Falkenberg, Lars‐Erik Kyhl, Signe Møgelmose, Arjun Ravi, Philippe Pinton   +7 more
wiley   +1 more source